

**Interim Financial Statements (Un-audited)  
1<sup>st</sup> Quarter Ended  
March 31, 2015**



**Beximco Pharmaceuticals Limited**

**Beximco Pharmaceuticals Limited**  
**Statement of Financial Position (Un-audited)**  
**As at March 31, 2015**

Taka '000

|   | Notes | As at<br>March 31, 2015 | As at<br>December 31, 2014 |
|---|-------|-------------------------|----------------------------|
| <b>ASSETS</b>   |       |                         |                            |
| <b>Non-Current Assets</b>                               |       |                         |                            |
| Property, Plant and Equipment- Carrying Value           | 3     | 20,915,523              | 20,393,279                 |
| Intangible Assets                                       |       | 236,843                 | 235,208                    |
| Investment in Shares                                    |       | 5,288                   | 5,760                      |
|   |       | <b>21,157,654</b>       | <b>20,634,247</b>          |
| <b>Current Assets</b>                                   |       |                         |                            |
| Inventories   | 4     | 2,544,666               | 2,493,657                  |
| Spares & Supplies                                       |       | 547,639                 | 554,184                    |
| Accounts Receivable                                     |       | 1,427,591               | 1,397,499                  |
| Loans, Advances and Deposits                            | 5     | 1,248,653               | 1,223,673                  |
| Short Term Investment                                   |       | 2,448,292               | 2,475,027                  |
| Cash and Cash Equivalents                               | 6     | 157,941                 | 222,239                    |
|   |       | <b>8,374,782</b>        | <b>8,366,279</b>           |
| <b>TOTAL ASSETS</b>                                     |       | <b>29,532,436</b>       | <b>29,000,526</b>          |
| <b>EQUITY AND LIABILITIES</b>                           |       |                         |                            |
| <b>Shareholders' Equity</b>                             |       |                         |                            |
| Issued Share Capital                                    |       | 3,678,517               | 3,678,517                  |
| Share Premium   |       | 5,269,475               | 5,269,475                  |
| Excess of Issue Price over Face Value of GDRs           |       | 1,689,637               | 1,689,637                  |
| Capital Reserve on Merger                               |       | 294,951                 | 294,951                    |
| Revaluation Surplus                                     |       | 1,262,358               | 1,299,220                  |
| Fair Value Gain on Investment                           |       | 1,837                   | 2,309                      |
| Retained Earnings                                       |       | 9,096,324               | 8,686,077                  |
|   |       | <b>21,293,099</b>       | <b>20,920,186</b>          |
| <b>Non-Current Liabilities</b>                          |       |                         |                            |
| Long Term Borrowings-Net off Current Maturity (Secured) | 7 A   | 771,889                 | 901,709                    |
| Liability for Gratuity and WPPF & Welfare Funds         |       | 764,816                 | 741,523                    |
| Deferred Tax Liability                                  |       | 1,754,275               | 1,729,361                  |
|   |       | <b>3,290,980</b>        | <b>3,372,593</b>           |
| <b>Current Liabilities and Provisions</b>               |       |                         |                            |
| Short Term Borrowings (Secured)                         |       | 3,326,468               | 3,153,121                  |
| Long Term Borrowings-Current Maturity (Secured)         | 7 B   | 654,328                 | 663,838                    |
| Creditors and Other Payables                            |       | 308,505                 | 357,711                    |
| Accrued Expenses  |       | 225,927                 | 164,283                    |
| Dividend Payable  |       | 248                     | 455                        |
| Income Tax Payable                                      |       | 432,881                 | 368,339                    |
|   |       | <b>4,948,357</b>        | <b>4,707,747</b>           |
| <b>TOTAL EQUITY AND LIABILITIES</b>                     |       | <b>29,532,436</b>       | <b>29,000,526</b>          |

*Nazmul Hassan*

**Nazmul Hassan**  
Managing Director

*Ali Nawaz*

**Ali Nawaz**  
Chief Financial Officer

**Beximco Pharmaceuticals Limited**  
**Statement of Profit or Loss and Other Comprehensive Income (Un-audited)**  
**For the 1<sup>st</sup> Quarter ended March 31, 2015**

|   |       | Taka '000                                       |   |
|---|-------|---|---|
|   | Notes | 1 <sup>st</sup> Quarter ended<br>March 31, 2015 | 1 <sup>st</sup> Quarter ended<br>March 31, 2014 |
| <b>Net Sales Revenue</b>                                      |       | <b>2,997,389</b>                                | <b>2,576,260</b>                                |
| Cost of Goods Sold  | 8     | (1,655,101)                                     | (1,439,165)                                     |
| <b>Gross Profit</b>   |       | <b>1,342,288</b>                                | <b>1,137,095</b>                                |
| <b>Operating Expenses</b>                                     |       | <b>(706,794)</b>                                | <b>(637,008)</b>                                |
| Administrative Expenses                                       | 9     | (105,830)                                       | (103,801)                                       |
| Selling, Marketing and Distribution Expenses                  | 10    | (600,964)                                       | (533,207)                                       |
| <b>Profit from Operations</b>                                 |       | <b>635,494</b>                                  | <b>500,087</b>                                  |
| Other Income  |       | 94,501  | 100,396   |
| Finance Cost  |       | (191,170)                                       | (175,360)                                       |
| <b>Profit Before Contribution to WPPF &amp; Welfare Funds</b> |       | <b>538,825</b>                                  | <b>425,123</b>                                  |
| Contribution to WPPF & Welfare Funds                          |       | (25,658)  | (20,244)  |
| <b>Profit Before Tax</b>                                      |       | <b>513,167</b>                                  | <b>404,879</b>                                  |
| <b>Income Tax Expenses</b>                                    |       | <b>(106,459)</b>                                | <b>(75,095)</b>                                 |
| Current Tax   |       | (114,869)                                       | (76,745)  |
| Deferred Tax  |       | 8,410   | 1,650   |
| <b>Profit After Tax</b>                                       |       | <b>406,708</b>                                  | <b>329,784</b>                                  |
| Other Comprehensive Income-                                   |       |   |   |
| Fair Value Loss on Investment in Listed Shares                |       | (472)   | (230)   |
| <b>Total Comprehensive Income</b>                             |       | <b>406,236</b>                                  | <b>329,554</b>                                  |
| Earnings Per Share (EPS) / Adjusted EPS                       | Tk.   | 1.11  | 0.90  |
| Number of Shares used to compute EPS                          |       | 367,851,652                                     | 367,851,652                                     |

*Nazmul Hassan*

**Nazmul Hassan**  
Managing Director

*Ali Nawaz*

**Ali Nawaz**  
Chief Financial Officer

**Beximco Pharmaceuticals Limited**  
**Statement of Changes in Equity (Un-audited)**  
**For the 1<sup>st</sup> Quarter ended March 31, 2015**

Taka '000

| As at March 31, 2015                                     |                  |                  |   |                           |                     |  |                    |                   |
|--|------------------|------------------|---|---------------------------|---------------------|--|--------------------|-------------------|
|  | Share Capital    | Share Premium    | Excess of Issue Price over Face Value of GDRs | Capital Reserve on Merger | Revaluation Surplus | Fair Value Gain / (Loss) on Investment | Retained Earnings  | Total             |
| <b>Balance as on January 01, 2015</b>                    | <b>3,678,517</b> | <b>5,269,475</b> | <b>1,689,637</b>                              | <b>294,951</b>            | <b>1,299,220</b>    | <b>2,309</b>                           | <b>8,686,077</b>   | <b>20,920,186</b> |
| Total Comprehensive Income for the period :              |                  |                  |   |                           |                     |  |                    |                   |
| Profit for the Period                                    | -                | -                | -   | -                         | -                   | -                                      | 406,708            | 406,708           |
| Other Comprehensive Income / (Loss)                      | -                | -                | -   | -                         | -                   | (472)                                  | -                  | (472)             |
| Adjustment for Depreciation on Revalued Assets           | -                | -                | -   | -                         | (3,539)             | -                                      | 3,539              | -                 |
| Adjustment for Deferred Tax on Revalued Assets           | -                | -                | -   | -                         | (33,323)            | -                                      | -                  | (33,323)          |
| <b>Balance as on March 31, 2015</b>                      | <b>3,678,517</b> | <b>5,269,475</b> | <b>1,689,637</b>                              | <b>294,951</b>            | <b>1,262,358</b>    | <b>1,837</b>                           | <b>9,096,324</b>   | <b>21,293,099</b> |
| <b>Number of Shares on March 31, 2015</b>                |                  |                  |   |                           |                     |  | <b>367,851,652</b> |                   |
| <b>Net Asset Value (NAV) Per Share on March 31, 2015</b> |                  |                  |   |                           |                     |  | <b>Tk. 57.89</b>   |                   |

| As at March 31, 2014                                     |                  |                  |   |                           |                     |  |                    |                   |
|--|------------------|------------------|---|---------------------------|---------------------|--|--------------------|-------------------|
|  | Share Capital    | Share Premium    | Excess of Issue Price over Face Value of GDRs | Capital Reserve on Merger | Revaluation Surplus | Fair Value Gain / (Loss) on Investment | Retained Earnings  | Total             |
| <b>Balance as on January 01, 2014</b>                    | <b>3,503,349</b> | <b>5,269,475</b> | <b>1,689,637</b>                              | <b>294,951</b>            | <b>1,349,579</b>    | <b>1,341</b>                           | <b>7,667,220</b>   | <b>19,775,552</b> |
| Total Comprehensive Income for the period:               |                  |                  |   |                           |                     |  |                    |                   |
| Profit for the Period                                    | -                | -                | -   | -                         | -                   | -                                      | 329,784            | 329,784           |
| Other Comprehensive Income / (Loss)                      | -                | -                | -   | -                         | -                   | (230)                                  | -                  | (230)             |
| Adjustment for Depreciation on Revalued Assets           | -                | -                | -   | -                         | (4,015)             | -                                      | 4,015              | -                 |
| Adjustment for Deferred Tax on Revalued Assets           | -                | -                | -   | -                         | (37,610)            | -                                      | -                  | (37,610)          |
| <b>Balance as on March 31, 2014</b>                      | <b>3,503,349</b> | <b>5,269,475</b> | <b>1,689,637</b>                              | <b>294,951</b>            | <b>1,307,954</b>    | <b>1,111</b>                           | <b>8,001,019</b>   | <b>20,067,496</b> |
| <b>Number of Shares on March 31, 2014</b>                |                  |                  |   |                           |                     |  | <b>350,334,907</b> |                   |
| <b>Net Asset Value (NAV) Per Share on March 31, 2014</b> |                  |                  |   |                           |                     |  | <b>Tk. 57.28</b>   |                   |

*Nazmul Hassan*

**Nazmul Hassan**  
Managing Director

*Ali Nawaz*

**Ali Nawaz**  
Chief Financial Officer

**Beximco Pharmaceuticals Limited**  
**Statement of Cash Flows (Un-audited)**  
**For the 1<sup>st</sup> Quarter ended March 31, 2015**

Taka '000

**1<sup>st</sup> Quarter ended**    **1<sup>st</sup> Quarter ended**  
**March 31, 2015**    **March 31, 2014**

**Cash Flows from Operating Activities :**

|   |                |                |
|---|----------------|----------------|
| Receipts from Customers and Others                  | 2,967,566      | 2,540,964      |
| Payments to Suppliers and Employees                 | (2,231,807)    | (2,054,259)    |
| <b>Cash Generated from Operations</b>               | <b>735,759</b> | <b>486,705</b> |
| Interest Paid                                       | (191,170)      | (175,360)      |
| Interest Received                                   | 93,596         | 99,311         |
| Income Tax Paid                                     | (50,327)       | (115,118)      |
| <b>Net Cash Generated from Operating Activities</b> | <b>587,858</b> | <b>295,538</b> |

**Cash Flows from Investing Activities :**

|  |                  |                  |
|--|------------------|------------------|
| Acquisition of Property, Plant and Equipment | (708,113)        | (212,106)        |
| Intangible Assets                            | (5,238)          | (7,265)          |
| Disposal of Property, Plant and Equipment    | 650              | 604              |
| Decrease/(Increase) in Short Term Investment | 26,735           | (519,413)        |
| <b>Net Cash Used in Investing Activities</b> | <b>(685,966)</b> | <b>(738,180)</b> |

**Cash Flows from Financing Activities**

|   |                 |                  |
|---|-----------------|------------------|
| Net Decrease in Long Term Borrowings                      | (139,330)       | (158,958)        |
| Net Increase in Short Term Borrowings                     | 173,347         | 139,927          |
| Dividend Paid   | (207)           | (84)             |
| <b>Net Cash Generated from Financing Activities</b>       | <b>33,810</b>   | <b>(19,115)</b>  |
| <b>Increase / (Decrease) in Cash and Cash Equivalents</b> | <b>(64,298)</b> | <b>(461,757)</b> |
| Cash and Cash Equivalents at Beginning of Period          | 222,239         | 595,733          |
| <b>Cash and Cash Equivalents at End of Period</b>         | <b>157,941</b>  | <b>133,976</b>   |

|   |            |                    |                    |
|---|------------|--------------------|--------------------|
| <b>Net Operating Cash Flow Per Share</b>                                  | <b>Tk.</b> | <b>1.60</b>        | <b>0.84</b>        |
| <b>Number of Shares used to compute Net Operating Cash Flow Per Share</b> |            | <b>367,851,652</b> | <b>350,334,907</b> |

*Nazmul Hassan*

**Nazmul Hassan**  
Managing Director

*Ali Nawaz*

**Ali Nawaz**  
Chief Financial Officer

**Beximco Pharmaceuticals Limited**  
**Selected Notes to the Financial Statements (Un-audited)**  
**For the 1<sup>st</sup> Quarter ended March 31, 2015**

**1. Reporting Entity**

Beximco Pharmaceuticals Limited (BPL/the Company) is a public company incorporated in Bangladesh in 1976. It commenced its manufacturing operation in 1980. The company is listed on Dhaka and Chittagong Stock Exchanges of Bangladesh and AIM of London Stock Exchange. The company is engaged in manufacturing and marketing of Pharmaceuticals Finished Formulation Products, Active Pharmaceutical Ingredients (APIs) and life saving Intravenous Fluids which it sells in the local as well as international markets.

**2. Basis of Preparation of Financial Statements**

These interim financial statements should be read in conjunction with the Financial Statements for the year ended December 31, 2014 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information.

The accounting policies used are consistent with those used in the Annual Financial Statements. The financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRSs). The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

Taka '000

As at  
**March 31, 2015**    **December 31, 2014**

**3. Property, Plant & Equipment**

|                                  |                          |                          |
|----------------------------------|--------------------------|--------------------------|
| Land                             | 3,343,741                | 3,343,741                |
| Building and Other Constructions | 6,410,640                | 6,410,090                |
| Plant and Machinery              | 10,601,451               | 10,573,116               |
| Furniture and Fixtures           | 199,944                  | 197,001                  |
| Transport and Vehicle            | 601,838                  | 596,846                  |
| Office Equipment                 | 392,698                  | 390,014                  |
|                                  | <b>21,550,312</b>        | <b>21,510,808</b>        |
| Less :Accumulated Depreciation   | (5,611,253)              | (5,425,449)              |
| <b>Net Book Value</b>            | <b>15,939,059</b>        | <b>16,085,359</b>        |
| Capital Work in Progress         | 4,976,464                | 4,307,920                |
| <b>Carrying Value</b>            | <b><u>20,915,523</u></b> | <b><u>20,393,279</u></b> |

|   | As at<br>March 31, 2015 | Taka '000<br>As at<br>December 31, 2014 |
|---|-------------------------|---|
| <b>4. Inventories</b>   |                         |   |
| Finished Goods  | 701,712                 | 633,692                                 |
| Raw and Packing Materials (Including Work in Process and Transit) | 1,688,457               | 1,710,090                               |
| Physician Sample  | 154,497                 | 149,875                                 |
|   | <u>2,544,666</u>        | <u>2,493,657</u>                        |
| <b>5. Loans, Advances and Deposits</b>                            |                         |   |
| Clearing & Forwarding   | 61,229                  | 54,354                                  |
| VAT   | 224,400                 | 217,516                                 |
| Security Deposit and Earnest Money                                | 28,409                  | 27,653                                  |
| Capital Expenditure / Project                                     | 50,030                  | 50,030                                  |
| Advance against Salary  | 54,826                  | 55,699                                  |
| Motor Cycle   | 116,435                 | 124,010                                 |
| Raw & Packing Material  | 423,512                 | 422,210                                 |
| Overseas Liaison Office   | 15,033                  | 15,033                                  |
| Others  | 274,779                 | 257,168                                 |
|   | <u>1,248,653</u>        | <u>1,223,673</u>                        |
| <b>6. Cash and Cash Equivalents</b>                               |                         |   |
| (a) Cash in Hand (Including Imprest Cash)                         | 2,975                   | 3,218                                   |
| (b) Cash at Bank:   |                         |   |
| (i) Current and FC Account  | 125,979                 | 190,574                                 |
| (ii) FDR Account  | 28,987                  | 28,447                                  |
|   | <u>157,941</u>          | <u>222,239</u>                          |
| <b>7. Long Term Borrowings:</b>                                   |                         |   |
| <b>A. Net off Current Maturity (Secured)</b>                      |                         |   |
| Project Loan  | 504,672                 | 608,901                                 |
| Obligation Under Finance leases                                   | 267,217                 | 292,808                                 |
|   | <u>771,889</u>          | <u>901,709</u>                          |
| <b>B. Current Maturity (Secured)</b>                              |                         |   |
| Project Loan  | 531,158                 | 536,347                                 |
| Obligation Under Finance leases                                   | 123,170                 | 127,491                                 |
|   | <u>654,328</u>          | <u>663,838</u>                          |

|  | Taka '000                                       |   |
|--|---|---|
|  | 1 <sup>st</sup> Quarter ended<br>March 31, 2015 | 1 <sup>st</sup> Quarter ended<br>March 31, 2014 |
| <b>8. Cost of Goods Sold</b>                           |   |   |
| Materials  | 1,186,001                                       | 1,024,132                                       |
| Factory Overhead                                       | 300,902   | 246,246   |
| Depreciation   | 168,198   | 168,787   |
|  | <u>1,655,101</u>                                | <u>1,439,165</u>                                |
| <b>9. Administrative Expenses</b>                      |   |   |
| Salary & Allowances                                    | 46,360  | 45,548  |
| Repairs & Maintenance                                  | 7,788   | 7,558   |
| Travelling & Conveyance                                | 5,826   | 4,708   |
| AGM, Company Secretarial and Regulatory Expense        | 6,347   | 7,006   |
| Depreciation   | 6,505   | 6,528   |
| Other Expenses   | 33,004  | 32,453  |
|  | <u>105,830</u>                                  | <u>103,801</u>                                  |
| <b>10 Selling, Marketing and Distribution Expenses</b> |   |   |
| Salary & Allowances                                    | 194,866   | 176,906   |
| Travelling & Conveyance                                | 83,576  | 73,548  |
| Market Research & New Products                         | 8,120   | 7,536   |
| Sample, Literature & Promotional Expenses              | 167,653   | 150,139   |
| Delivery Expense                                       | 75,574  | 65,092  |
| Depreciation and Amortization                          | 14,754  | 14,967  |
| Other Expenses   | 56,421  | 45,019  |
|  | <u>600,964</u>                                  | <u>533,207</u>                                  |

**11. Proposed Dividend for 2014**

The Board of Directors of the Company in its meeting held on 27 April, 2015 has proposed 10% cash and 5% stock dividend for the year 2014 which is subject to approval in the annual general meeting to be held on June 13, 2015. The company consistently follows the policy of recognising proposed dividend after the approval by its shareholders in the annual general meeting. Hence proposed dividend for 2014 has not been accounted for in this interim financial statements.

*Nazmul Hassan*

**Nazmul Hassan**  
Managing Director

*Ali Nawaz*

**Ali Nawaz**  
Chief Financial Officer